( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Dr. Bader Unissa*1, Maleeha Wajid2, Sameera Afroz3, Mohammed Hamza4 and Mohammed Mujtaba5


Study Objective: To compare the safety, effectiveness, and affordability of erythropoietin alfa with Darbepoetin alfa for achieving increasing haemoglobin concentration in ESRD patients associated with dialysis to treat anemia. Design: A prospective, comparative study. Methods: In this randomised study, end-stage renal disease (ESRD) patients on dialysis were considered, who are anaemic or whose haemoglobin levels are<10gm/Dl. Among a total population of 80 patients, half of them received erythropoietin alfa and the other half received Darbepoetin alfa via I.V or S.C route of administration and was then observed for the next 26 weeks. The efficacy was compared by observing the mean change in haemoglobin level from baseline to the end of the study. Safety was also evaluated by comparing ADRs observed in both groups. Results: In the patient population (n = 80), 40 patients were given erythropoietin alfa (Epofit 4k IU) and the remaining 40 patients were given Darbepoetin alfa (Cresp 40mcg). The mean change in haemoglobin levels to achieve the target haemoglobin levels (10.5-12.5 g/Dl) between these 2 groups during monthly follow up and at the end of 6 months was superior in group A 1(65.2%) than in group B (52.2%). The safety of the drug was evaluated by comparing the ADRs observed in each group. Group b- with Darbepoetin alfa (23.2%) showed significantly similar ADRs when compared to group A- with erythropoietin alfa (21.2%). Although the ADR’s were not severe. Conclusion: Both the drugs are safe and effective for treating anaemia in dialysis patients, but erythropoietin alfa tends to be superior to Darbepoetin alfa. Darbepoetin alfa is superior as it is a long- acting drug which is generally administered only 1 to 2 times a week, whereas erythropoietin alfa is a short-acting drug which is administered 3 times a week (Doses are adjusted according to HB levels). Although both the drugs are safe and effective, erythropoietin alfa is preferred due to its availability, cost effectiveness, and domestic production.

Keywords: .

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 April 2024 Issue has been Published, Kindly check it on


    APRIL 2024 issue has been successfully launched on APRIL 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia